HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

Trizivir

Subscribe to New Research on Trizivir

a combination of Ziagen (DIDEOXYNUCLEOSIDES), lamivudine & zidovudine; Trizivir is tradename

Networked: 11 relevant articles (0 outcomes, 3 trials/studies)

Drug Context: Research Results

Experts

1.	Valencia, M E: 1 article (01/2012)
2.	Moreno, V: 1 article (01/2012)
3.	Shang, Judith: 1 article (01/2009)
4.	Kongnyuy, Eugene J: 1 article (01/2009)
5.	Wiysonge, Charles Shey: 1 article (01/2009)
6.	Shey, Muki: 1 article (01/2009)
7.	d'Ettorre, Gabriella: 1 article (11/2006)
8.	Mastroianni, Claudio M: 1 article (11/2006)
9.	Vullo, Vincenzo: 1 article (11/2006)
10.	Handforth, Jennifer: 1 article (01/2004)

Related Diseases

1.	Infection 11/01/2003 - "Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial." 01/01/2012 - "The patient was under clinically and virologically effective treatment with Trizivir (zidovudine, lamivudine and abacavir) when it was decided to initiate treatment for the chronic HCV infection with peginterferon and ribavirin. " 02/14/2003 - "Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection."
2.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2009 - "A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS." 01/01/2004 - "A major concern is the apparently inferior virologic control of triple NRTI therapy as demonstrated in the AIDS Clinical Trials Group A5095 study with zidovudine/lamivudine/abacavir (Trizivir) combination in adults. "
3.	Lipodystrophy 01/01/2003 - "Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study." 01/01/2003 - "To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks. "
4.	HIV Infections (HIV Infection) 12/01/2000 - "FDA approves Trizivir for HIV infection." 11/01/2006 - "Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir." 01/01/2009 - "The aim of this review was to evaluate the effects of Trizivir, a fixed-dose combination of three NRTIs (abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. " 01/01/2009 - "A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS."
5.	Hypersensitivity (Allergy) 01/01/2009 - "We found no significant differences between Trizivir and either the PI or NNRTI on CD4+ cell counts (standardized mean difference -0.01, 95% CI -0.11 to 0.09, heterogeneity P=0.59, I(2)=0%), severe adverse events (RR 1.41, 95% CI 0.61 to 3.25, heterogeneity P=0.03, I(2)=73%) and hypersensitivity reactions (RR 4.04, 95% CI 0.41 to 40.02, heterogeneity P=0.03, I(2)=72%). " 04/01/2003 - "The incidence of possible hypersensitivity reaction in the Trizivir trade mark arm was 10%. " 05/01/2002 - "Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. "

Related Drugs and Biologics

1.	abacavir (Ziagen)
2.	Zidovudine (Retrovir)
3.	Lamivudine (3TC)
4.	zidovudine drug combination lamivudine
5.	Ribavirin (Virazole)
6.	Penicillin G Benzathine (LPG)
7.	Carbon Monoxide
8.	lamivudine drug combination abacavir
9.	tenofovir

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)